History: The part of oncolytic infections in tumor treatment is increasingly studied. was visualized using immunocytochemistry. Statistical difference between treatment organizations was determined using two-way ANOVA. Outcomes: Rigvir? (10%, quantity/quantity) decreased cell viability in FM-9, RD, AGS, A549, HDFa, HPAF?II and MSC cell lines by 67-100%. HaCaT cell viability was affected while Rigvir? had no… Continue reading History: The part of oncolytic infections in tumor treatment is increasingly